Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
525.82
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about United Therapeutics Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It
↗
August 12, 2025
The company is working through a patent battle that could seriously hamper sales of its new drug.
Via
Investor's Business Daily
Topics
Intellectual Property
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Excels as a High-Quality Pick in the Caviar Cruise Stock Screen
↗
August 09, 2025
United Therapeutics Corp (UTHR) excels in the Caviar Cruise stock screen, showcasing strong revenue growth, high ROIC, robust cash flow, and a debt-free balance sheet—ideal for long-term investors.
Via
Chartmill
Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Fits Peter Lynch’s Growth at a Reasonable Price (GARP) Strategy
↗
August 06, 2025
UNITED THERAPEUTICS CORP (UTHR) aligns with Peter Lynch's GARP strategy, boasting steady earnings growth (16.88% EPS), low PEG (0.70), zero debt, and strong profitability (17.31% ROE). A solid biotech...
Via
Chartmill
Joby Aviation Soars Amidst eVTOL Hype, Signaling a New Era for Air Mobility
August 04, 2025
Joby Aviation (NYSE: JOBY) has recently experienced a significant surge in its stock value, fueled by a burgeoning "aviation buzz" surrounding the electric vertical takeoff and landing (eVTOL) aircraft...
Via
MarketMinute
Topics
Economy
Emissions
Earnings Scheduled For July 30, 2025
↗
July 30, 2025
Via
Benzinga
Preview: United Therapeutics's Earnings
↗
July 29, 2025
Via
Benzinga
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
August 01, 2025
From
United Therapeutics Corporation
Via
Business Wire
Forecasting The Future: 8 Analyst Projections For United Therapeutics
↗
July 31, 2025
Via
Benzinga
Earnings Summary on United Therapeutics
↗
July 31, 2025
Via
The Motley Fool
Topics
Intellectual Property
United Therapeutics Stock Slides On Q2 Earnings: The Details
↗
July 30, 2025
United Therapeutics Corp (NASDAQ:UTHR) reported second-quarter financial results before the market open on Wednesday. Here's a rundown of the report.
Via
Benzinga
United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates
July 30, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its GAAP profit of $6.41 per share...
Via
StockStory
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
July 30, 2025
From
United Therapeutics Corporation
Via
Business Wire
What To Expect From United Therapeutics’s (UTHR) Q2 Earnings
July 28, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.
Via
StockStory
Topics
Artificial Intelligence
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?
↗
July 24, 2025
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.
Via
Investor's Business Daily
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Prime Value Pick with Strong Fundamentals and Undervalued Potential
↗
July 24, 2025
UNITED THERAPEUTICS CORP (UTHR) is a top value stock with strong fundamentals—low P/E, high profitability, zero debt, and steady growth—making it a standout in biotech.
Via
Chartmill
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
July 16, 2025
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the...
Via
StockStory
Topics
Artificial Intelligence
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
July 16, 2025
From
United Therapeutics Corporation
Via
Business Wire
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment
July 15, 2025
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)
July 15, 2025
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Moderna (NASDAQ:MRNA) and its peers.
Via
StockStory
Topics
Artificial Intelligence
1 Cash-Producing Stock with Impressive Fundamentals and 2 to Keep Off Your Radar
July 15, 2025
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...
Via
StockStory
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks
July 14, 2025
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Strong Candidate for GARP Investors
↗
July 09, 2025
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy.
Via
Chartmill
1 Value Stock with Impressive Fundamentals and 2 to Turn Down
July 09, 2025
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...
Via
StockStory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Potential Undervalued Biotech Stock
↗
July 02, 2025
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a financially healthy biotech stock with strong profitability and an undervalued price. Its low P/E and high margins make it a candidate for value investors.
Via
Chartmill
1 Mid-Cap Stock with Exciting Potential and 2 to Ignore
July 01, 2025
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...
Via
StockStory
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (9 Ratings)
↗
June 30, 2025
Via
Benzinga
Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday
↗
June 30, 2025
Via
Benzinga
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
June 24, 2025
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
June 23, 2025
From
United Therapeutics Corporation
Via
Business Wire
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Strong Candidate for GARP Investors
↗
June 17, 2025
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers growth at a reasonable price, with strong profitability, no debt, and a PEG ratio of 0.68. A solid pick for long-term investors.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
